USFDA Approval Boost for Zydus!** 💊
Zydus Lifesciences Limited has received **final approvals from the USFDA** for:
✅ **Ivermectin Tablets USP, 3 mg**
✅ **Dapsone Tablets USP, 25 mg & 100 mg**
📌 **Key Highlights:**
• Ivermectin (anti-parasitic) – US annual sales: **$14.8 Mn**
• Dapsone (leprosy & skin treatment) – US annual sales: **$8.4 Mn**
• Manufacturing at Ahmedabad SEZ facilities
• Total ANDA approvals now stand at **434**
💡 This strengthens Zydus’ US generics portfolio and reinforces its steady expansion strategy in regulated markets.
Pharma stocks often react positively to USFDA approvals as they open new revenue streams and improve product pipeline visibility. Keep this on your radar 👀
---
📢 **Follow for daily stock market updates, technical levels & research-backed insights.**
Free learning. No noise. Only clarity.
---
